Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Burning Rock Biotech Limited (NASDAQ:BNR, the ", Company", or ", Burning Rock", ))))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2023 before the U.S. market opens on May 30, 2023. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2023.
While the Company has not completed the preparation of its financial statements for the first quarter of 2023, it expects to report a moderately positive revenue growth on a year-over-year basis, driven by a strong growth rebound in March, reversing the year-over-year decreasing trend in January-February. Total test volumes (central-laboratory and in-hospital combined) in March 2023 increased by approximately 29% year-over-year, driven by strong growth of the in-hospital channel.
Please register in advance of the conference using the link provided below and dial in 15 minutes prior to the call, using participant dial-in numbers and unique registrant ID which would be provided upon registering.
Posted In: BNR